Existing investors stepped up with enthusiasm to an oversubscribed $65 million internal round at Nimbus Therapeutics that will enable the Cambridge, Mass.-based company to accelerate pipeline programs and examine additional targets in metabolic, immuno-oncology (I-O) and autoimmune disease. Each of the company's current investors participated in the round, including Atlas Venture, SR One, Lilly Ventures, Bill Gates, Pfizer Venture Investments, Lightstone Ventures and Schrödinger.